Veritas’ Research Arm Cannevert Signs a Material Transfer

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
58
Veritas’ Research Arm Cannevert Signs a Material Transfer Agreement with the Institute for Medical Cannabis of Puerto Rico

VANCOUVER, British Columbia, Dec. 05, 2017 (GLOBE NEWSWIRE) -- Veritas Pharma Inc. (CSE:VRT) (OTC:VRTHF) (Frankfurt: 2VP ), (“Veritas” or the “Company”) announces its research arm, Cannevert Therapeutics Ltd. ( “CTL” ) has signed a Material Transfer Agreement with the Institute for Medical Cannabis ( “IMC” ) Corporation of Puerto Rico. IMC will provide Cannevert with specific cannabis strains for upcoming human studies in the US territory.

IMC is the first licensed medical cannabis company under the State Department Medical Cannabis Health Code to supply a variety of the high quality medical cannabis products for the medical community.  It has a state of the art facility in Ponce that provides cultivation, extraction, formulation, multiple forms of production, and research using the best, award winning strains, technology and processes in the industry. 

IMC operates in a 44,000-square-foot building with 15,000 square feet of indoor cannabis under lights with an additional 1,800 square feet of ISO Class 7 cleanroom class manufacturing space. For more information about IMC, please visit their website at http://imc-pr.com .

Veritas’ CEO, Dr. Lui Franciosi, stated “We are pleased that Cannevert has identified a reputable producer that is focused on providing certified quality products, educating the medical community on the potential benefits of cannabis, and conducting clinical research on its products. They will enable us to get medical grade strains of interest into the clinic and scientifically evaluated against different kinds of pain.”

About Veritas Pharma Inc.

Veritas Pharma Inc. is an emerging-stage pharmaceutical and IP development company, who, through its 80% owned Cannevert Therapeutics Ltd. ("CTL"), is advancing the science behind medical cannabis. It is the Company aim, through its investment in CTL, to develop the most effective cannabis strains (cultivars) specific to pain, nausea, epilepsy and PTSD, solving the critical need for clinical data to support medical marijuana claims. CTL’s unique value proposition uses a low-cost research and development model to help drive shareholder value, and speed-to-market. Veritas investment in CTL is led by strong management team, bringing together veteran academic pharmacologists, anesthetists & chemists. The company's commercial mission is to patent protect CTL’s IP (cultivars & strains) and sell or license to cancer clinics, insurance industry and pharma, targeting multi-billion dollar global markets.

Veritas Pharma Inc. is a publicly traded company which trades in three countries including Canada, on the Canadian Securities Exchange under the ticker VRT; in the United States, on the OTC under the ticker VRTHF; and in Germany, on the Frankfurt exchange under the ticker 2VP.

For more information, please visit our website: veritaspharmainc.com

On behalf of the Board of Directors

" Dr. Lui Franciosi" Dr. Lui Franciosi President and Chief Executive Officer

Further information about the Company is available on our website at www.veritaspharmainc.com or under our profile on SEDAR at www.sedar.com and on the CSE website at www.thecse.com.

Investor and Public Relations Contact Veritas Pharma Inc. Sam Eskandari Telephone: +1.416.918.6785 Email: ir@veritaspharmainc.com Website: www.veritaspharmainc.com

The CSE has not reviewed, nor approved or disapproved the content of this press release.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

GomSpace's €8M Lunar Deal Pushes Mission Ambitions

Updated Category News Views 63

Moon hardware is where small-space dreams either grow teeth or chew through cash, and GomSpace has just taken another meaningful bite. The company has secured an €8 million, or 89.1 million Swedish kronor, contract for the second phase of a lunar mission program with an unnamed leading North American space company. For GOMX, this is not some vague laboratory...

Continue Reading
Northstar's December Test: Metrics Over More Promises

Updated Category News Views 43

A shingle recycler earns its stripes when the machinery behaves, not when the slide deck does. Northstar Clean Technologies is putting Empower Calgary under a brighter light on December 1, pairing its third-quarter 2026 results with a comprehensive production update and a new set of operating metrics. For shareholders, especially those following OTCQB:ROOOF, this is the...

Continue Reading
Robert Half's Parent Support Earns Fortune Recognition

Updated Category News Views 73

A workplace award rarely moves a staffing stock by itself, and it shouldn’t. Still, Fortune naming Robert Half among its Best Workplaces for Parents for 2026 is more than decorative corporate wallpaper. In the talent business, the company’s own ability to recruit, retain and support people is part of the product. Clients hire Robert Half because they need skilled...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
FAA Funding Gridlock Raises Aviation Reliability Risk

Updated Category News Views 81

Friday’s radar and communications trouble delivered the sort of warning nobody in aviation can shrug off: the machinery behind the flight board is getting old, fragile, and far too dependent on people improvising around it. Thousands of flights were delayed or canceled when air traffic control facilities became unstable, according to the Southwest Airlines Pilots...

Continue Reading
LKQ’s Europe ERP Mess Turns Into a Credibility Test

Updated Category News Views 60

A software rollout should not be able to punch a company in the teeth twice, yet LKQ shareholders have watched precisely that ugly movie in 2026. The October 23 disclosure was a real gut-check: an immediate CEO departure, a $16 million net loss, and renewed acknowledgement that the German enterprise-resource-planning rollout was disrupting Europe. Shares fell $5.05, or...

Continue Reading
L’Oréal’s Women of Worth Shows Why Brand Patience Matters

Updated Category News Views 105

Twenty-one years is a long time to keep a corporate promise from turning into wallpaper. L’Oréal Paris gathered its 2026 Women of Worth class at the Ebell in Los Angeles on November 18, recognizing 10 nonprofit leaders working on problems that do not yield to a glitzy evening or a tidy slogan. That distinction matters. Cancer survivorship, trafficking prevention,...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 87

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 76

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
Innogen's Arcera Deal Tests Its GLP-1 Global Reach

Updated Category News Views 115

A License Deal With Actual Cash Attached Drug licensing announcements can smell like expensive perfume: plenty of promise, hard to tell what is really in the bottle. This one at least arrives with a concrete number. Innogen Pharmaceuticals will receive US$38 million in upfront and near-term milestone payments from Arcera Life Sciences for Efsubaglutide Alfa, including a...

Continue Reading

Top 5 Most Recently Viewed Articles

How a $100 Investment in Builders FirstSource Transformed

Updated Category News Views 173

Understanding Builders FirstSource's Growth Journey Investing in the stock market can sometimes feel daunting, but Builders FirstSource (NYSE: BLDR) has presented an impressive case for savvy investors over the last five years. This company has not only survived the ups and downs of the market but has also outperformed it significantly. With a remarkable 28.17% annualized...

Continue Reading
Adagene Strengthens Leadership with Axel Hoos as Advisor

Updated Category News Views 99

Adagene Appoints Renowned Immuno-Oncology Expert Adagene Inc. (Nasdaq: ADAG) has marked a significant milestone in its journey towards transforming cancer treatment by appointing Dr. Axel Hoos as an Executive Advisor. With an impressive background in immuno-oncology, Dr. Hoos brings a wealth of knowledge and experience that aligns perfectly with Adagene's mission....

Continue Reading
Suffolk County Transit Orders 132 Modern Buses from NFI

Updated Category News Views 122

NFI Group Inc. Awarded Contract for New Buses A recent agreement between NFI Group Inc. and Suffolk County Transit has been finalized, marking an essential step in modernizing the county's public transportation system. The contract, which spans five years, encompasses the delivery of up to 132 next-generation buses, including a combination of hybrid-electric and...

Continue Reading
Decoding Love: The Real Patterns of Relationships

Updated Category News Views 131

The Relationship Maze: More Than Meets the Eye Love ain't just a simple spark over a fancy dinner, let me tell you. In Dr. Bernadette Marson’s ‘The Relationship Code,’ she digs into seventy-seven elements gnawing at why relationships can crumble or thrive. It’s like a blueprint of human entanglements—a veritable explorer’s guide to the vast, wild creation we...

Continue Reading
Understanding BP's Recent Options Activity and Market Insights

Updated Category News Views 129

Understanding BP's Options Activity Investors with substantial capital have recently adopted a positive outlook on BP. This inspires interest among retail traders. Our analysis of publicly available options data indicates notable trading activity involving BP. An uptick of this nature often hints that informed investors anticipate significant developments regarding the...

Continue Reading